Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
20.15
+0.10 (0.50%)
Dec 18, 2025, 2:39 PM EST - Market open
Innoviva Employees
Innoviva had 127 employees as of December 31, 2024. The number of employees increased by 15 or 13.39% compared to the previous year.
Employees
127
Change (1Y)
15
Growth (1Y)
13.39%
Revenue / Employee
$3,059,220
Profits / Employee
$1,002,709
Market Cap
1.51B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 127 | 15 | 13.39% |
| Dec 31, 2023 | 112 | 11 | 10.89% |
| Dec 31, 2022 | 101 | 96 | 1,920.00% |
| Dec 31, 2021 | 5 | 0 | - |
| Dec 31, 2020 | 5 | -1 | -16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INVA News
- 5 days ago - U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents - Business Wire
- 6 days ago - US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections - Reuters
- 6 days ago - Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea - Business Wire
- 23 days ago - Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference - Business Wire
- 6 weeks ago - Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress - Business Wire
- 2 months ago - Antheia Appoints Eric d'Esparbes as Chief Financial Officer - PRNewsWire
- 2 months ago - Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025 - Business Wire
- 2 months ago - Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025 - Business Wire